Form 4: BioLife Solutions EVP Sells Shares Under 10b5-1 Plan

Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions, sold 123 shares of common stock at $26.34 per share on November 12, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Aby J. Mathew, the EVP & Chief Scientific Officer of BioLife Solutions, executed a sale of 123 common stock shares.
• The transaction occurred on November 12, 2024, at a price of $26.34 per share.
• This sale was conducted under a pre-existing Rule 10b5-1 trading plan adopted on February 8, 2021.
• The purpose of the sale was to cover tax withholding obligations related to the vesting of restricted stock shares.
• Following the transaction, Mathew directly owns 317,046 shares of BioLife Solutions common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-existing plan, with no indication of positive or negative sentiment. It is a neutral event.

Industry Context

This is a routine transaction for executives who use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading. It is common for executives to sell shares to cover tax obligations related to vesting stock.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among publicly traded companies to allow insiders to sell shares without the appearance of trading on non-public information.
• Many executives at comparable companies such as Thermo Fisher Scientific, Danaher, and Agilent Technologies also utilize 10b5-1 plans for similar purposes.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a small transaction by an executive under a pre-arranged plan.

Key Dates

Keywords

BioLife Solutions, BLFS, insider trading, Form 4, stock sale, Rule 10b5-1, executive, share transaction, equity securities